Galecto rebrands as Damora Therapeutics (DMRA); $535M cash; DMR-001 IND mid-2026

Damora Therapeutics, Inc.

Name changed from Galecto to Damora Therapeutics; trades on Nasdaq as DMRA from March 10, 2026.
Preliminary cash and cash equivalents ~$535M as of Feb 28, 2026, including ~$316M from Feb 2026 public offering.
DMR-001 (anti-mutCALR antibody) IND/CTA on track for mid-2026; proof-of-concept data expected mid-2027.
DMR-002 IND/CTA planned for H2 2026; DMR-003 IND/CTA in 2027.
Acquisition of privately held Damora closed Nov 2025 with ~$285M private investment.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Damora Therapeutics, Inc.: Amended certificate of incorporation to change company name from Galecto, Inc. to Damora Therapeutics, Inc (effective 2026-03-10).

Change: charter amendment
Effective: 2026-03-10

Exact text from the filing

On March 6, 2026, the Company filed with the Secretary of State of the State of Delaware an amendment to its Amended and Restated Certificate of Incorporation to change the name of the Company from "Galecto, Inc." to "Damora Therapeutics, Inc." (the "Name Change Amendment"). The Name Change Amendment became effective at 12:01 a.m. Eastern Time on March 10, 2026.

View on SEC.gov

40 governance changes filed in the last 30 days. Browse all governance changes →

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-099404

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.